EAM Investors LLC Acquires Shares of 71,815 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

EAM Investors LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 71,815 shares of the company’s stock, valued at approximately $3,976,000.

Several other hedge funds have also modified their holdings of TARS. Crowley Wealth Management Inc. bought a new position in Tarsus Pharmaceuticals in the 4th quarter worth approximately $25,000. R Squared Ltd bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth $53,000. HighTower Advisors LLC bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth $207,000. Summit Investment Advisors Inc. lifted its stake in shares of Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company’s stock valued at $213,000 after acquiring an additional 244 shares during the period. Finally, Victory Capital Management Inc. bought a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $223,000. 90.01% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on TARS shares. Jefferies Financial Group boosted their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Guggenheim reissued a “buy” rating and set a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. HC Wainwright reaffirmed a “buy” rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Barclays lowered their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Finally, Oppenheimer increased their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $63.67.

Insider Activity

In related news, insider Dianne C. Whitfield sold 2,137 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $107,085.07. Following the transaction, the insider now directly owns 46,355 shares in the company, valued at approximately $2,322,849.05. The trade was a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bobak R. Azamian sold 7,131 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $330,093.99. Following the completion of the sale, the chief executive officer now owns 70,720 shares of the company’s stock, valued at approximately $3,273,628.80. This represents a 9.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock worth $1,581,173 in the last quarter. Corporate insiders own 8.25% of the company’s stock.

Tarsus Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ TARS opened at $49.12 on Wednesday. The firm has a 50 day moving average price of $47.92 and a 200 day moving average price of $47.44. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market cap of $1.89 billion, a P/E ratio of -12.89 and a beta of 0.94. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.